Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Dicerna Pharmaceuticals (DRNA) PT Raised to $20 at SunTrust Robinson Humphrey
September 5, 2018 9:48 AM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $20.00 (from $15.00) while maintaining a Buy rating after the company reported PoC data from the ongoing Phase I PHYOX study in primary hyperoxaluria I and... More



